Amyris (AMRS) Tops Q2 EPS by 6c

Amyris (NASDAQ: AMRS) reported Q2 EPS of ($0.06), $0.06 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $12.4 million versus the consensus estimate of $15.23 million.

"We’re very pleased with reaching our best ever quarter of signing new collaborations that have already funded more than $20 million of payments this year and are expected to more than underpin our full year targets,” said John Melo, Amyris President & CEO. “We are encouraged by these results and our success in delivering on our stated milestones and goals thus far this year. Additional progress in the coming months is anticipated to further grow our customer base, improve our balance sheet and further position the company as the leader in industrial biotechnology.”

For earnings history and earnings-related data on Amyris (AMRS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79